CTRP6 Inhibitor Suppresses Complement Alternative Pathway
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack an effective solution for addressing autoimmune diseases related to complement activation, particularly in suppressing the complement alternative pathway, which is involved in various inflammatory and autoimmune conditions.
Innovation Solution
The use of CTRP6 as a novel inhibitor of the complement alternative pathway, formulated into a pharmaceutical composition to prevent or treat autoimmune diseases by specifically suppressing complement activation, including rheumatoid arthritis and type 1 diabetes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional complement activation inhibitors are used, then complement-mediated immune responses are suppressed, but they cannot specifically target the alternative pathway which is involved in autoimmune diseases
Solution Approach 1:
The invention segments the complement inhibition function by developing CTRP6 that specifically targets the alternative pathway while leaving the classical and lectin pathways unaffected. This is achieved through the unique C1q domain structure of CTRP6 that selectively binds to C3, the key component of the alternative pathway, thereby resolving the contradiction between pathway-specific suppression and broad complement coverage.
Solution Approach 2:
The invention applies local quality by endowing CTRP6 with a specific molecular characteristic (C1q domain structure) that enables selective interaction with C3 in the alternative pathway. This localized functional specialization allows the protein to suppress only the problematic alternative pathway while maintaining normal function of other complement pathways, addressing the specificity versus versatility contradiction.
2Reliability
If CTRP6 is used to specifically suppress the alternative pathway, then autoimmune disease treatment is improved, but the mechanism of action is novel and unproven compared to existing therapies
Solution Approach 1:
The invention performs preliminary action by conducting extensive in vitro and in vivo studies to establish the relationship between CTRP6 and alternative pathway suppression before clinical application. The patent documents comprehensive experimental evidence showing CTRP6's ability to inhibit C3 activation and reduce autoimmune disease symptoms in animal models, thereby building a knowledge foundation that reduces the information loss risk for future clinical use.
Solution Approach 2:
The invention implements feedback by using the discovered mechanism of CTRP6 action (alternative pathway suppression) to guide further research and development. The patent establishes a feedback loop where experimental results on CTRP6's effect on complement activation inform the design of therapeutic strategies and dosing regimens for autoimmune disease treatment, reducing the uncertainty associated with novel mechanisms.
3Adaptability or versatility
If broad complement inhibition is achieved, then various complement-mediated conditions are treated, but non-specific suppression may affect protective immune functions
Solution Approach 1:
The invention applies inversion by reversing the conventional approach of broad complement inhibition. Instead of suppressing all complement pathways and hoping to spare protective functions, CTRP6 specifically targets the alternative pathway which is implicated in autoimmune disease pathogenesis. This inverted strategy treats the specific harmful pathway while preserving the protective functions of the classical and lectin pathways, resolving the contradiction between treatment versatility and immune protection.
Data Source
AI summary
Provided are methods of suppressing complement alternative pathway in a mammalian subject in need thereof, comprising administering to said subject a therapeutically effective amount of C1q and tumor necrosis factor related protein 6 (CTRP6) or a functional analog thereof.